Clinical Trials Browser

Withdrawn × Insulinoma × Endocrine × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Phase 2 Withdrawn

Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT02108782 2017-07-19

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Phase 2 Withdrawn

Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Clinical Trials

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Pasireotide in Hyperinsulinemic Hypoglycemia

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors